The Thesis (Dual-Axis Correlation)
(Right Click -> Print -> Save as PDF)
The Insurance Hedge
Asymmetric Asset Correlation: De-risking Schedule 3 Exposure
Insight: While the broader cannabis market suffers from commodity price compression (Red), NDEV revenue is derived from fixed insurance premiums (Green). This creates a structural hedge against wholesale volatility.
Novus (NDEV) | Institutional Briefing Strictly Confidential Page 1
The "Green Rush" Trap
Cost Structure Comparison: Why MSOs Bleed Cash
$10M
Gross
Revenue
Revenue
$4M
COGS
$3M
OpEx
$2.5M
280E TAX
$0.5M
Net
Income
Income
Key Insight: Traditional operators pay taxes on Gross Profit, destroying free cash flow. Notice the massive red 280E Tax bar compared to the tiny Net Income. NDEV bypasses this tax trap entirely via insurance exemptions.
Novus (NDEV) | Institutional Briefing Strictly Confidential Page 2
The "Regulatory Arbitrage" Model
Turning Non-Deductible Spend into Tax-Deductible Premiums
Patient Wallet
($$$)
($$$)
Tax Deductible Premium
Novus
Insurance Pool
Insurance Pool
Clean Receivables
NDEV
Revenue
Revenue
Complimentary Cannabis Benefit (0% Cost to Patient)
The Mechanism: By bundling cannabis as a "complimentary benefit" inside a compliant health plan, we convert the consumer's non-deductible expense into a tax-advantaged insurance premium.
Novus (NDEV) | Institutional Briefing Strictly Confidential Page 3
Competitive Moat & Readiness
Why NDEV is the only "Pure Play" for Schedule 3
| Criterion | Rec Brands (Hype Stocks) | Traditional MSOs (Cultivators) | Novus (NDEV) (Med-Tech) |
|---|---|---|---|
| HIPAA Compliant | ✕ | ⚠ Partial | ✓ YES |
| Insurance Codes (CPT) | ✕ | ✕ | ✓ YES |
| 280E Tax Exempt | ✕ | ✕ | ✓ YES |
| FDA Trial Ready | ✕ | ⚠ Low | ✓ High |
Investment Summary: NDEV is not a farm. It is a financial infrastructure play purpose-built for the medical reality of Schedule 3.
Contact: CEO Office | strictly-confidential@novus.com
Novus (NDEV) | Institutional Briefing Strictly Confidential Page 4
